(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 3.72% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.84%.
Phibro Animal Health's revenue in 2026 is $1,464,325,000.On average, 7 Wall Street analysts forecast PAHC's revenue for 2026 to be $61,531,698,888, with the lowest PAHC revenue forecast at $58,613,199,336, and the highest PAHC revenue forecast at $63,761,108,268. On average, 7 Wall Street analysts forecast PAHC's revenue for 2027 to be $63,923,247,132, with the lowest PAHC revenue forecast at $60,761,539,284, and the highest PAHC revenue forecast at $66,112,121,796.
In 2028, PAHC is forecast to generate $66,112,121,796 in revenue, with the lowest revenue forecast at $62,747,740,368 and the highest revenue forecast at $68,909,017,200.